CRISPR Tx’s CTX110 Reports a Comparable Efficacy and Safety Profile to Autologous CD19 CAR-Ts; 2seventy’s Launch Delayed to November 2021; bluebird and Poseida Appoint New Leadership Roles
Here is a brief preview of this blast: A series of cell therapy-related news items have been observed: